{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:20:06Z","timestamp":1791148806828,"version":"4.1.0"},"reference-count":303,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Rheinland-Pfalz Stiftung fuer Innovation","award":["1032"],"award-info":[{"award-number":["1032"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.autrev.2015.07.003","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T00:38:07Z","timestamp":1436402287000},"page":"1005-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Genetics and novel aspects of therapies in systemic lupus erythematosus"],"prefix":"10.1016","volume":"14","author":[{"given":"Manfred","family":"Relle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Scorletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2010.09.007","article-title":"Updating on the pathogenesis of systemic lupus erythematosus","volume":"10","author":"Gualtierotti","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3949\/ccjm.76a.gr005","article-title":"Lupus update: perspective and clinical pearls","volume":"76","author":"Manzi","year":"2009","journal-title":"Cleve Clin J Med"},{"issue":"22","key":"10.1016\/j.autrev.2015.07.003_bb1065","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/archinte.164.22.2435","article-title":"Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting","volume":"164","author":"Narain","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2015.07.003_bb1070","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/584374","article-title":"Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus","volume":"2012","author":"Relle","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2015.07.003_bb1075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0961203309346653","article-title":"Molecular mimicry in systemic lupus erythematosus","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb1080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"129-49","key":"10.1016\/j.autrev.2015.07.003_bb1085","article-title":"Molecular mimicry: Antigen sharing by parasite and host and its consequences","volume":"98","author":"Damian","year":"1964","journal-title":"Am Nat"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.11.009","article-title":"A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth","volume":"281","author":"Bei","year":"2009","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1542\/pir.27-9-323","article-title":"Systemic lupus erythematosus in children and adolescents","volume":"27","author":"Gottlieb","year":"2006","journal-title":"Pediatr Rev\/Am Acad Pediatr"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb1100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jpeds.2007.09.019","article-title":"Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study","volume":"152","author":"Hiraki","year":"2008","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1567-5769(01)00046-7","article-title":"Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus","volume":"1","author":"Rider","year":"2001","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1590\/S0482-50042011000500006","article-title":"Prolactin, estradiol and anticardiolipin antibodies in premenopausal women with systemic lupus erythematosus: a pilot study","volume":"51","author":"Tiskievicz","year":"2011","journal-title":"Rev Bras Reumatol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002281-199909000-00005","article-title":"The role of sex hormones in systemic lupus erythematosus","volume":"11","author":"Lahita","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203308090026","article-title":"Sex hormones and systemic lupus erythematosus","volume":"17","author":"Petri","year":"2008","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1130","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1002\/art.21436","article-title":"Pituitary hormones and systemic lupus erythematosus","volume":"52","author":"Li","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4-5","key":"10.1016\/j.autrev.2015.07.003_bb1135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0961203314559636","article-title":"17-beta-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB\/WF1 mice","volume":"24","author":"Bassi","year":"2015","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clim.2013.03.003","article-title":"Sexual disparities in the incidence and course of SLE and RA","volume":"149","author":"Tedeschi","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb1145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1749-6632.2009.05293.x","article-title":"Nonhormonal explanations for sex discrepancy in human illness","volume":"1193","author":"Lockshin","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"7497","key":"10.1016\/j.autrev.2015.07.003_bb1150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature13206","article-title":"Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators","volume":"508","author":"Bellott","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0961203309350755","article-title":"Review: Male systemic lupus erythematosus: a review of sex disparities in this disease","volume":"19","author":"Lu","year":"2010","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1191\/0961203303lu334oa","article-title":"Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus","volume":"12","author":"Arbuckle","year":"2003","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1165","first-page":"1339","article-title":"Gender differences in a cohort of Puerto Ricans with systemic lupus erythematosus","volume":"49","author":"Mayor","year":"2003","journal-title":"Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb1170","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.111061","article-title":"Differences between male and female systemic lupus erythematosus in a multiethnic population","volume":"39","author":"Tan","year":"2012","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1175","first-page":"220","article-title":"Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations","volume":"17","author":"Ward","year":"1990","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1180","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.22375","article-title":"Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort","volume":"56","author":"Andrade","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1191\/096120398678919697","article-title":"A reason for the rarity of male lupus","volume":"7","author":"Wallace","year":"1998","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1195","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/archderm.142.3.371","article-title":"Sex hormones and the genesis of autoimmunity","volume":"142","author":"Ackerman","year":"2006","journal-title":"Arch Dermatol"},{"issue":"6-7","key":"10.1016\/j.autrev.2015.07.003_bb1200","doi-asserted-by":"crossref","first-page":"A502","DOI":"10.1016\/j.autrev.2011.12.003","article-title":"Progesterone and autoimmune disease","volume":"11","author":"Hughes","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1205","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrrheum.2014.144","article-title":"Modulation of autoimmune rheumatic diseases by oestrogen and progesterone","volume":"10","author":"Hughes","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0889-857X(21)00891-7","article-title":"Systemic lupus erythematosus","volume":"16","author":"Hochberg","year":"1990","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2015.07.003_bb1215","first-page":"iii3","article-title":"Epidemiology of connective tissue disorders","volume":"45","author":"Gaubitz","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2015.07.003_bb1220","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/604892","article-title":"Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis","volume":"2012","author":"Schwartzman-Morris","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.38239","article-title":"The incidence and prevalence of systemic lupus erythematosus, 2002\u20132004: The Georgia Lupus Registry","volume":"66","author":"Lim","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1240","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/art.1780380914","article-title":"Incidence of systemic lupus erythematosus. Race and gender differences","volume":"38","author":"McCarty","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb1245","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3899\/jrheum.081141","article-title":"Ethnic differences in pediatric systemic lupus erythematosus","volume":"36","author":"Hiraki","year":"2009","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1250","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/art.22079","article-title":"The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient","volume":"54","author":"Patel","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb1255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2 Suppl. 2","key":"10.1016\/j.autrev.2015.07.003_bb1260","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.jaci.2009.10.067","article-title":"Immunologic rheumatic disorders","volume":"125","author":"Joseph","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1265","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.autrev.2011.10.020","article-title":"Systemic lupus erythematosus one disease or many?","volume":"11","author":"Agmon-Levin","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb1270","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1275","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.rdc.2005.01.009","article-title":"Review of classification criteria for systemic lupus erythematosus","volume":"31","author":"Petri","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1280","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1285","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2015.07.003_bb1290","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar1009","article-title":"B cell abnormalities in systemic lupus erythematosus","volume":"5","author":"Grammer","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb1295","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.autrev.2013.03.014","article-title":"Prevalence and clinical significance of rare antinuclear antibody patterns","volume":"12","author":"Vermeersch","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.autrev.2014.10.003","article-title":"A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients","volume":"14","author":"Yaniv","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.07.003_bb1305","article-title":"Arraying autoantibodies in SLE \u2013 lessons learned","volume":"30","author":"Wang","year":"2015","journal-title":"Curr Mol Med"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1310","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2012.02.013","article-title":"Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis","volume":"12","author":"Op De Beeck","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1191\/0961203306lu2308oa","article-title":"Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis","volume":"15","author":"Jaekell","year":"2006","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1320","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00296-011-1962-3","article-title":"Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4","volume":"32","author":"Julkunen","year":"2012","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1325","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jcp.53.6.424","article-title":"The use of laboratory tests in the diagnosis of SLE","volume":"53","author":"Egner","year":"2000","journal-title":"J Clin Pathol"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1330","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0961203310362995","article-title":"Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test","volume":"19","author":"Antico","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1335","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1038\/jid.1993.18","article-title":"Anti-Ro(SS-A) HLA-DR3-positive women: the interrelationship between some ANA negative, SS, SCLE, and NLE mothers and SS\/LE overlap female patients","volume":"100","author":"Provost","year":"1993","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.autrev.2012.07.002","article-title":"Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis","volume":"12","author":"Bizzaro","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb1345","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.autrev.2012.02.012","article-title":"The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)","volume":"11","author":"Mahler","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1350","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/rheumatology\/kei150","article-title":"A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus","volume":"45","author":"Allen","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb1355","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.autrev.2012.09.004","article-title":"Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients","volume":"12","author":"Tani","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1360","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0305-70","article-title":"Taming lupus","volume":"292","author":"Zouali","year":"2005","journal-title":"Sci Am"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1370","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1177\/0961203310374486","article-title":"Infections in systemic lupus erythematosus","volume":"19","author":"Navarra","year":"2010","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1375","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s10096-014-2098-7","article-title":"Infections and systemic lupus erythematosus","volume":"33","author":"Esposito","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1380","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/0961203309103870","article-title":"The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients","volume":"18","author":"Zhou","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.07.003_bb1385","doi-asserted-by":"crossref","first-page":"370516","DOI":"10.1155\/2012\/370516","article-title":"Epstein-Barr virus and systemic lupus erythematosus","volume":"2012","author":"Draborg","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb1390","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/RHU.0b013e3181f4cf52","article-title":"Cytomegalovirus as a trigger for systemic lupus erythematosus","volume":"16","author":"Perez-Mercado","year":"2010","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1395","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s10067-014-2738-4","article-title":"Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review","volume":"33","author":"Serio","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1400","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/0961203311411597","article-title":"Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers","volume":"20","author":"Akhter","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1405","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0961203310379871","article-title":"Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares","volume":"20","author":"Matrat","year":"2011","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1410","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2012.03.009","article-title":"Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers","volume":"12","author":"Sciascia","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1415","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005792-200105000-00001","article-title":"Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families","volume":"80","author":"Michel","year":"2001","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.1780350310","article-title":"A revised estimate of twin concordance in systemic lupus erythematosus","volume":"35","author":"Deapen","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1425","first-page":"867","article-title":"The application of genetic epidemiology to systemic lupus erythematosus","volume":"14","author":"Hochberg","year":"1987","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2796.1992.tb00500.x","article-title":"Systemic lupus erythematosus and related systemic diseases in a nationwide twin cohort: an increased prevalence of disease in MZ twins and concordance of disease features","volume":"231","author":"Jarvinen","year":"1992","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1435","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autrev.2013.09.004","article-title":"The cryptic interplay between systemic lupus erythematosus and infections","volume":"13","author":"Rigante","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1440","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1445","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.autrev.2011.09.008","article-title":"Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance","volume":"11","author":"Sawla","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1450","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780190201","article-title":"Histocompatibility antigens in systemic lupus erythematosus","volume":"19","author":"Goldberg","year":"1976","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2133.1977.tb12535.x","article-title":"Histocompatibility antigens in discoid and systemic lupus erythematosus","volume":"96","author":"Millard","year":"1977","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb1460","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/art.1780230815","article-title":"HLA-DRw3 and systemic lupus erythematosus","volume":"23","author":"Scherak","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1465","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1084\/jem.148.5.1198","article-title":"Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains","volume":"148","author":"Andrews","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2015.07.003_bb1470","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","article-title":"Murine models of systemic lupus erythematosus","volume":"37","author":"Theofilopoulos","year":"1985","journal-title":"Adv Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb1475","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.iy.09.040191.001331","article-title":"Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease","volume":"9","author":"Cohen","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb1480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-065X.1995.tb00068.x","article-title":"The Yaa gene model of systemic lupus erythematosus","volume":"144","author":"Izui","year":"1995","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1485","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0952-7915(99)00039-4","article-title":"Genetic dissection of systemic lupus erythematosus","volume":"11","author":"Wakeland","year":"1999","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1490","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/clim.2001.5079","article-title":"NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci","volume":"100","author":"Waters","year":"2001","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1495","first-page":"1362","article-title":"Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A\/H2B\/DNA subnucleosomes","volume":"101","author":"Mohan","year":"1998","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb1500","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/1074-7613(94)90100-7","article-title":"Polygenic control of susceptibility to murine systemic lupus erythematosus","volume":"1","author":"Morel","year":"1994","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1505","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4049\/jimmunol.159.1.454","article-title":"Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity","volume":"159","author":"Mohan","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb1510","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2010.63","article-title":"Genetics of SLE: evidence from mouse models","volume":"6","author":"Morel","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1515","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1074-7613(00)80088-6","article-title":"Epistatic modifiers of autoimmunity in a murine model of lupus nephritis","volume":"11","author":"Morel","year":"1999","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1520","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4049\/jimmunol.175.2.1062","article-title":"Epistatic suppression of systemic lupus erythematosus: fine mapping of Sles1 to less than 1 mb","volume":"175","author":"Subramanian","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb1525","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.01.008","article-title":"Genetic susceptibility to SLE: Recent progress from GWAS","volume":"41","author":"Cui","year":"2013","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1189\/jlb.0212095","article-title":"Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways","volume":"92","author":"Vaughn","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2015.00079","article-title":"Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity","volume":"6","author":"Vogelpoel","year":"2015","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00352843","article-title":"The polymorphic Fc gamma receptor II gene maps to human chromosome 1q","volume":"29","author":"Grundy","year":"1989","journal-title":"Immunogenetics"},{"issue":"4956","key":"10.1016\/j.autrev.2015.07.003_bb0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1126\/science.2139735","article-title":"Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination","volume":"248","author":"Qiu","year":"1990","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0030","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/ejhg.2010.56","article-title":"Evidence for both copy number and allelic (NA1\/NA2) risk at the FCGR3B locus in systemic lupus erythematosus","volume":"18","author":"Morris","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0035","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1136\/ard.2009.123588","article-title":"Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples","volume":"69","author":"McKinney","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1756-185X.2010.01469.x","article-title":"Fc gamma R IIIB polymorphisms: their association with clinical manifestations and autoantibodies in SLE patients from western India","volume":"13","author":"Pradhan","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1046\/j.1523-1755.2003.00873.x","article-title":"Fc gamma R-SLEm-ai. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis","volume":"63","author":"Karassa","year":"2003","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0050","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1096\/fasebj.5.12.1916092","article-title":"Fc receptors and immunoglobulin binding factors","volume":"5","author":"Fridman","year":"1991","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0055","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","article-title":"Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome","volume":"45","author":"Lessard","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1620\/tjem.236.185","article-title":"FcgammaRIIB gene polymorphisms are associated with disease risk and clinical manifestations of systemic lupus erythematosus in koreans","volume":"236","author":"Jeon","year":"2015","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ng2046","article-title":"FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity","volume":"39","author":"Fanciulli","year":"2007","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1756-185X.12342","article-title":"FCGR3B copy number loss rather than gain is a risk factor for systemic lupus erythematous and lupus nephritis: a meta-analysis","volume":"18","author":"Yuan","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0075","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1084\/jem.20020165","article-title":"Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-\/-) mice","volume":"195","author":"Bolland","year":"2002","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.autrev.2015.07.003_bb0080","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1073\/pnas.0608889104","article-title":"Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria","volume":"104","author":"Clatworthy","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.autrev.2015.07.003_bb0085","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1073\/pnas.0915133107","article-title":"A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus","volume":"107","author":"Willcocks","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0090","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1177\/0961203309106921","article-title":"Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside","volume":"18","author":"Zandman-Goddard","year":"2009","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1323","article-title":"A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes","volume":"36","author":"Bottini","year":"2004","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.smim.2006.03.008","article-title":"Role of PTPN22 in type 1 diabetes and other autoimmune diseases","volume":"18","author":"Bottini","year":"2006","journal-title":"Semin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1086\/422827","article-title":"A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis","volume":"75","author":"Begovich","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.20771","article-title":"Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus","volume":"52","author":"Orozco","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1086\/423790","article-title":"Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE","volume":"75","author":"Kyogoku","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"18","key":"10.1016\/j.autrev.2015.07.003_bb0120","doi-asserted-by":"crossref","first-page":"14718","DOI":"10.1074\/jbc.M010051200","article-title":"Structure and expression of the TREX1 and TREX2 3\u2032 -->5\u2032 exonuclease genes","volume":"276","author":"Mazur","year":"2001","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0125","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2013.78","article-title":"Gene-function studies in systemic lupus erythematosus","volume":"9","author":"Crispin","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0130","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ng2091","article-title":"Mutations in the gene encoding the 3\u2032\u20135\u2032 DNA exonuclease TREX1 are associated with systemic lupus erythematosus","volume":"39","author":"Lee-Kirsch","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/76032","article-title":"Features of systemic lupus erythematosus in Dnase1-deficient mice","volume":"25","author":"Napirei","year":"2000","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/91070","article-title":"Mutation of DNASE1 in people with systemic lupus erythematosus","volume":"28","author":"Yasutomo","year":"2001","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2007.10.017","article-title":"Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease","volume":"131","author":"Yang","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0150","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/MCB.14.7.4342","article-title":"Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation","volume":"14","author":"Yamamoto","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0155","article-title":"Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody","volume":"27","author":"Zheng","year":"2013","journal-title":"Hum Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0160","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0165","doi-asserted-by":"crossref","first-page":"e111991","DOI":"10.1371\/journal.pone.0111991","article-title":"A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene","volume":"9","author":"Ciccacci","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.autrev.2015.07.003_bb0170","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/hmg\/ddn184","article-title":"A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5","volume":"17","author":"Sigurdsson","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0175","doi-asserted-by":"crossref","first-page":"e1000084","DOI":"10.1371\/journal.pgen.1000084","article-title":"Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus","volume":"4","author":"Taylor","year":"2008","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrg2571","article-title":"Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies","volume":"10","author":"Harley","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.autrev.2015.07.003_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1196\/annals.1423.015","article-title":"A genome-wide study of lupus: preliminary analysis and data release","volume":"1110","author":"Cervino","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/gene.2014.23","article-title":"GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region","volume":"15","author":"Armstrong","year":"2014","journal-title":"Genes Immun"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0195","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.81","article-title":"Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci","volume":"40","author":"Harley","year":"2008","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0200","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMoa0707865","article-title":"Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX","volume":"358","author":"Hom","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng.71","article-title":"A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus","volume":"40","author":"Nath","year":"2008","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/ard.2009.120543","article-title":"ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry","volume":"69","author":"Kim-Howard","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/gene.2009.30","article-title":"Admixture in Hispanic Americans: its impact on ITGAM association and implications for admixture mapping in SLE","volume":"10","author":"Molineros","year":"2009","journal-title":"Genes Immun"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0220","doi-asserted-by":"crossref","first-page":"e57082","DOI":"10.1371\/journal.pone.0057082","article-title":"Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells","volume":"8","author":"Fossati-Jimack","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0225","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar4566","article-title":"Resequencing the susceptibility gene, ITGAM, identifies two functionally deleterious rare variants in systemic lupus erythematosus cases","volume":"16","author":"Roberts","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0230","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/art.30356","article-title":"Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus","volume":"63","author":"Ramos","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4940","key":"10.1016\/j.autrev.2015.07.003_bb0235","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.2404338","article-title":"Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells","volume":"247","author":"Dymecki","year":"1990","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/annrheumdis-2011-200085","article-title":"Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK","volume":"71","author":"Castillejo-Lopez","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1-2","key":"10.1016\/j.autrev.2015.07.003_bb0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/emboj\/21.1.83","article-title":"BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor","volume":"21","author":"Yokoyama","year":"2002","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0250","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ng.472","article-title":"Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus","volume":"41","author":"Han","year":"2009","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0255","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ng.468","article-title":"Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus","volume":"41","author":"Gateva","year":"2009","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0260","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1007\/s11033-010-0573-5","article-title":"Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis","volume":"38","author":"Fan","year":"2011","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00403-010-1029-4","article-title":"The association of the BLK gene with SLE was replicated in Chinese Han","volume":"302","author":"Zhang","year":"2010","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0270","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2011-200987","article-title":"Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein","volume":"71","author":"Delgado-Vega","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0275","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.4049\/jimmunol.1402736","article-title":"Concordance of increased B1 cell subset and lupus phenotypes in mice and humans is dependent on BLK expression levels","volume":"194","author":"Wu","year":"2015","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0280","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/icb.2011.76","article-title":"Blk haploinsufficiency impairs the development, but enhances the functional responses, of MZ B cells","volume":"90","author":"Samuelson","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ng.79","article-title":"Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus","volume":"40","author":"Kozyrev","year":"2008","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0290","doi-asserted-by":"crossref","first-page":"e1001323","DOI":"10.1371\/journal.pgen.1001323","article-title":"Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production","volume":"7","author":"Chung","year":"2011","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0295","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1002\/art.21416","article-title":"Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus","volume":"52","author":"Flores-Borja","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0300","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2310\/6650.2001.34042","article-title":"B-cell kinase lyn deficiency in patients with systemic lupus erythematosus","volume":"49","author":"Liossis","year":"2001","journal-title":"J Invest Med"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0305","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0310","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1357-2725(96)00104-5","article-title":"Lyn, a src-like tyrosine kinase","volume":"29","author":"Hibbs","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0315","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20020515","article-title":"Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity","volume":"196","author":"Hibbs","year":"2002","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/gene.2009.19","article-title":"Genetic associations of LYN with systemic lupus erythematosus","volume":"10","author":"Lu","year":"2009","journal-title":"Genes Immun"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ng.582","article-title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci","volume":"42","author":"Stahl","year":"2010","journal-title":"Nat Genet"},{"issue":"7145","key":"10.1016\/j.autrev.2015.07.003_bb0330","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Wellcome Trust Case Control C","year":"2007","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0335","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ng.200","article-title":"Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus","volume":"40","author":"Graham","year":"2008","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0340","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2009.31","article-title":"Meta-analysis and imputation identifies a 109kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations","volume":"10","author":"Bates","year":"2009","journal-title":"Genes Immun"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0345","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ng.202","article-title":"Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus","volume":"40","author":"Musone","year":"2008","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0350","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.27190","article-title":"The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population","volume":"62","author":"Shimane","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0355","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1089\/gtmb.2012.0096","article-title":"Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis","volume":"16","author":"Lee","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.766","article-title":"Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus","volume":"43","author":"Adrianto","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2015.07.003_bb0365","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/207578","article-title":"Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population","volume":"2010","author":"Kawasaki","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0370","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/gene.2009.39","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"10","author":"Moser","year":"2009","journal-title":"Genes Immun"},{"issue":"25","key":"10.1016\/j.autrev.2015.07.003_bb0375","doi-asserted-by":"crossref","first-page":"14705","DOI":"10.1016\/S0021-9258(18)77165-2","article-title":"The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein","volume":"265","author":"Opipari","year":"1990","journal-title":"J Biol Chem"},{"issue":"5488","key":"10.1016\/j.autrev.2015.07.003_bb0380","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1126\/science.289.5488.2350","article-title":"Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice","volume":"289","author":"Lee","year":"2000","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0385","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0390","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.33318","article-title":"Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus","volume":"64","author":"Zhou","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0395","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/art.33354","article-title":"Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus","volume":"64","author":"Hughes","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2015.07.003_bb0400","doi-asserted-by":"crossref","first-page":"ii56","DOI":"10.1136\/annrheumdis-2012-202351","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"72","author":"Rullo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0405","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.berh.2009.04.005","article-title":"Challenges of ethnicity in SLE","volume":"23","author":"Kumar","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0410","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","article-title":"Interferons and their actions","volume":"56","author":"Pestka","year":"1987","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0415","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"Ronnblom","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0420","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0425","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0435","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall'era","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5546","key":"10.1016\/j.autrev.2015.07.003_bb0440","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0445","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2013.02.013","article-title":"Anti-interferon alpha treatment in SLE","volume":"148","author":"Kirou","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0455","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors","volume":"23","author":"Liu","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"5421","key":"10.1016\/j.autrev.2015.07.003_bb0460","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type 1 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0465","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ni.1990","article-title":"IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses","volume":"12","author":"Krausgruber","year":"2011","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0470","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ng1782","article-title":"A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus","volume":"38","author":"Graham","year":"2006","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0475","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clim.2014.06.001","article-title":"IRF5-mediated signaling and implications for SLE","volume":"153","author":"Lazzari","year":"2014","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0480","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/ard.2008.097642","article-title":"STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk","volume":"68","author":"Abelson","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.autrev.2015.07.003_bb0485","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1177\/0961203313504479","article-title":"A redundant epistatic interaction between IRF5 and STAT4 of the type I interferon pathway in susceptibility to lupus and rheumatoid arthritis","volume":"22","author":"Kim","year":"2013","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0490","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cellimm.2011.07.014","article-title":"Targeting interferon regulatory factors to inhibit activation of the type I IFN response: implications for treatment of autoimmune disorders","volume":"271","author":"Sweeney","year":"2011","journal-title":"Cell Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0495","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0500","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"issue":"14","key":"10.1016\/j.autrev.2015.07.003_bb0505","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","article-title":"Complement deficiency states and associated infections","volume":"48","author":"Skattum","year":"2011","journal-title":"Mol Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0510","first-page":"1128","article-title":"Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus","volume":"21","author":"Sullivan","year":"1994","journal-title":"J Rheumatol"},{"issue":"2-3","key":"10.1016\/j.autrev.2015.07.003_bb0515","first-page":"149","article-title":"Molecular genetics of the major histocompatibility linked complement genes","volume":"6","author":"Colten","year":"1983","journal-title":"Springer Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0520","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/gene.2011.39","article-title":"Molecular basis of hereditary C1q deficiency \u2013 revisited: identification of several novel disease-causing mutations","volume":"12","author":"Schejbel","year":"2011","journal-title":"Genes Immun"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0525","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/0961203313486950","article-title":"Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy","volume":"22","author":"Troedson","year":"2013","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0530","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/art.1780390419","article-title":"Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families","volume":"39","author":"Slingsby","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0535","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002281-200301000-00010","article-title":"Rheumatic syndromes associated with complement deficiency","volume":"15","author":"Barilla-LaBarca","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0540","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/ard.46.6.457","article-title":"HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens","volume":"46","author":"Smolen","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0545","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1191\/096120399678847560","article-title":"Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus","volume":"8","author":"Tjernstrom","year":"1999","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0550","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrrheum.2010.86","article-title":"Geoepidemiology of autoimmune rheumatic diseases","volume":"6","author":"Shapira","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0555","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.4049\/jimmunol.181.10.7367","article-title":"Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice","volume":"181","author":"Menke","year":"2008","journal-title":"J Immunol"},{"issue":"1-2","key":"10.1016\/j.autrev.2015.07.003_bb0560","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12016-007-0031-x","article-title":"Pathophysiology of cutaneous lupus erythematosus","volume":"33","author":"Lin","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0565","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3892\/etm.2013.960","article-title":"Effects of ultraviolet B exposure on DNA methylation in patients with systemic lupus erythematosus","volume":"5","author":"Zhu","year":"2013","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaut.2009.03.007","article-title":"The genetics and epigenetics of autoimmune diseases","volume":"33","author":"Hewagama","year":"2009","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0575","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clim.2009.05.011","article-title":"T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus","volume":"132","author":"Zhou","year":"2009","journal-title":"Clin Immunol"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2015.07.003_bb0580","doi-asserted-by":"crossref","first-page":"J135","DOI":"10.1016\/j.jaut.2011.11.001","article-title":"Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus","volume":"38","author":"Strickland","year":"2012","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0585","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1745-7254.2008.00739.x","article-title":"Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients","volume":"29","author":"Mi","year":"2008","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0590","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1521-6616(03)00206-7","article-title":"DNA methylation and autoimmune disease","volume":"109","author":"Richardson","year":"2003","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0595","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.4049\/jimmunol.0802412","article-title":"IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation","volume":"18","author":"Garaud","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0600","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/931018","article-title":"Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus","volume":"2010","author":"Zhao","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0605","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.4049\/jimmunol.172.6.3652","article-title":"Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells","volume":"172","author":"Kaplan","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0610","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2009.06.010","article-title":"DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus","volume":"56","author":"Luo","year":"2009","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0615","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/08916930903374832","article-title":"Key role of ERK pathway signaling in lupus","volume":"43","author":"Gorelik","year":"2010","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0620","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.24436","article-title":"MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins","volume":"60","author":"Tang","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0625","doi-asserted-by":"crossref","first-page":"e10344","DOI":"10.1371\/journal.pone.0010344","article-title":"Identification of unique microRNA signature associated with lupus nephritis","volume":"5","author":"Te","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0630","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/0961203307084158","article-title":"Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients","volume":"16","author":"Dai","year":"2007","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0635","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","article-title":"MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1","volume":"184","author":"Pan","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0640","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/art.30196","article-title":"MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1","volume":"63","author":"Zhao","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0645","first-page":"804","article-title":"Abnormal histone modification patterns in lupus CD4+ T cells","volume":"35","author":"Hu","year":"2008","journal-title":"J Rheumatol"},{"issue":"13","key":"10.1016\/j.autrev.2015.07.003_bb0650","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/0961203311413412","article-title":"Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells","volume":"20","author":"Zhou","year":"2011","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0655","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H","article-title":"Roles of histone acetyltransferases and deacetylases in gene regulation","volume":"20","author":"Kuo","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.autrev.2015.07.003_bb0660","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/371832","article-title":"Physical and functional HAT\/HDAC interplay regulates protein acetylation balance","volume":"2011","author":"Peserico","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"14","key":"10.1016\/j.autrev.2015.07.003_bb0665","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/0961203309104869","article-title":"Abnormal expression pattern of histone demethylases in CD4(+) T cells of MRL\/lpr lupus-like mice","volume":"18","author":"Long","year":"2009","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0670","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/art.39108","article-title":"Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus","volume":"67","author":"Aranow","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0675","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.4049\/jimmunol.176.12.7143","article-title":"The epigenetic face of systemic lupus erythematosus","volume":"176","author":"Ballestar","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0680","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4419-8216-2_9","article-title":"A new epigenetic challenge: systemic lupus erythematosus","volume":"711","author":"Javierre","year":"2011","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0685","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clim.2014.09.002","article-title":"Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application","volume":"155","author":"Guo","year":"2014","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0690","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9767","key":"10.1016\/j.autrev.2015.07.003_bb0695","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0700","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2011.04.029","article-title":"The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus","volume":"10","author":"Arnaud","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0705","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2011.04.027","article-title":"Refractory disease in systemic lupus erythematosus","volume":"10","author":"Campar","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0710","first-page":"373","article-title":"The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0715","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","article-title":"The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review","volume":"43","author":"Sutton","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0720","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","article-title":"Current and novel therapeutics in the treatment of systemic lupus erythematosus","volume":"127","author":"Yildirim-Toruner","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0725","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e32834456bf","article-title":"Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action","volume":"23","author":"Katz","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0730","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group","volume":"324","author":"The Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0735","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","article-title":"High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus","volume":"66","author":"Toubi","year":"2005","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0740","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1191\/096120301668222237","article-title":"High-dose intravenous immunoglobulins for lupus nephritis--a salvage immunomodulation","volume":"10","author":"Rauova","year":"2001","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0745","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.1.2.153","article-title":"IVIG in autoimmunity and cancer \u2013 efficacy versus safety","volume":"1","author":"Sherer","year":"2002","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0750","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/41.4.367","article-title":"The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases","volume":"41","author":"Pyne","year":"2002","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0755","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/CRIAI:29:3:219","article-title":"Intravenous immunoglobulin therapy and systemic lupus erythematosus","volume":"29","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5 Suppl. 68","key":"10.1016\/j.autrev.2015.07.003_bb0760","first-page":"S126","article-title":"Glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Mosca","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2015.07.003_bb0765","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.autrev.2013.02.001","article-title":"Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new","volume":"12","author":"Newman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0770","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2012.12.001","article-title":"The use of glucocorticoids in systemic lupus erythematosus. After 60years still more an art than science","volume":"12","author":"Luijten","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"16","key":"10.1016\/j.autrev.2015.07.003_bb0775","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM200010193431610","article-title":"Treatment of lupus nephritis \u2013 a work in progress","volume":"343","author":"Falk","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-99-1-1","article-title":"Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up","volume":"99","author":"Carette","year":"1983","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.autrev.2015.07.003_bb0785","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0790","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2010.135186","article-title":"Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.07.003_bb0795","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1749-6632.2011.06263.x","article-title":"Treatment of systemic lupus erythematosus: new advances in targeted therapy","volume":"1247","author":"Lo","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0800","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.07.003_bb0805","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.1177\/096120330501400107","article-title":"Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0810","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0815","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1741-7015-11-120","article-title":"Novel therapeutic agents in clinical development for Systemic Lupus Erythematosus","volume":"11","author":"Jordan","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0820","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.autrev.2011.07.006","article-title":"Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events","volume":"11","author":"Murdaca","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0825","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2014.08.020","article-title":"The efficacy of novel B cell biologics as the future of SLE treatment: a review","volume":"13","author":"Kamal","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.07.003_bb0830","article-title":"Upcoming biological therapies in systemic lupus erythematosus","volume":"28","author":"Sciascia","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0835","article-title":"New biologic therapy for systemic lupus erythematosus","volume":"7","author":"Ding","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0840","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human AntiInterferon-monoclonal antibody, in systemic lupus erythematosus: A phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0845","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0850","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0855","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0961203312469692","article-title":"Epratuzumab for systemic lupus erythematosus","volume":"22","author":"Wallace","year":"2013","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0860","first-page":"3982s","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0865","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/03009740500417791","article-title":"T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB\/WF1 lupus-prone mice is associated with autoantibody levels and nephritis","volume":"35","author":"Enghard","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0870","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1681\/ASN.2004111014","article-title":"Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice","volume":"16","author":"Schwarting","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0875","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cyto.2011.08.026","article-title":"The role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of systemic lupus erythematosus","volume":"56","author":"Postal","year":"2011","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0880","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0885","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.2010.438","article-title":"Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice","volume":"79","author":"Menke","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2015.07.003_bb0890","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0895","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/art.24658","article-title":"A polymorphism within IL21R confers risk for systemic lupus erythematosus","volume":"60","author":"Webb","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0900","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1172\/JCI110579","article-title":"Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus","volume":"69","author":"Alcocer-Varela","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.07.003_bb0905","article-title":"Inflammatory cytokines in systemic lupus erythematosus","volume":"432595","author":"Ohl","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.autrev.2015.07.003_bb0910","article-title":"Current state of evidence on \u201coff label\u201d therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland - a consensus report","volume":"9","author":"Aringer","year":"2011","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0915","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14740338.2015.986455","article-title":"Safety of off-label biologicals in systemic lupus erythematosus","volume":"14","author":"Aringer","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0920","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.autrev.2015.07.003_bb0925","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.07.003_bb0930","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2741\/3719","article-title":"Understanding rituximab function and resistance: implications for tailored therapy","volume":"16","author":"Amoroso","year":"2011","journal-title":"Front Biosci-Landmrk"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0935","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2012.01.004","article-title":"Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice","volume":"143","author":"Boross","year":"2012","journal-title":"Immunol Lett"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb0940","first-page":"4029","article-title":"Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): Results from the randomized, double-blind phase II\/III study EXPLORER","volume":"58","author":"Merrill","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb0945","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0950","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2015.07.003_bb0955","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.10.013","article-title":"Rituximab \u2013 shadow, illusion or light?","volume":"11","author":"van Vollenhoven","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb0960","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.autrev.2012.02.005","article-title":"Rituximab-it was the best of times, it was the worst of times","volume":"11","author":"Isenberg","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb0965","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb0970","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases","volume":"45","author":"Alten","year":"2013","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0975","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb0980","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/RHU.0b013e31823ecd73","article-title":"Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis","volume":"18","author":"Makol","year":"2012","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb0985","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/0961203312441046","article-title":"Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus","volume":"21","author":"Maeshima","year":"2012","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2015.07.003_bb0990","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/rheumatology\/kes072","article-title":"Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus","volume":"51","author":"Garcia-Hernandez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.07.003_bb0995","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007834","article-title":"Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab","volume":"2012","author":"Kamata","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"9","key":"10.1016\/j.autrev.2015.07.003_bb1000","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrneph.2012.141","article-title":"B-cell depletion in the treatment of lupus nephritis","volume":"8","author":"Gregersen","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1005","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2015.07.003_bb1010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: First targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"issue":"9783","key":"10.1016\/j.autrev.2015.07.003_bb1015","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0140-6736(11)60912-4","article-title":"Belimumab for systemic lupus erythematosus","volume":"377","author":"Chiche","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","article-title":"B-cell targeted therapies in systemic lupus erythematosus successes and challenges","volume":"27","author":"Harvey","year":"2013","journal-title":"Biodrugs"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1025","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2015.07.003_bb1030","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2015.07.003_bb1035","doi-asserted-by":"crossref","DOI":"10.1186\/ar2959","article-title":"B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin","volume":"12","author":"Dillon","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2015.07.003_bb1040","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2015.07.003_bb1045","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2015.07.003_bb1050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T18:28:01Z","timestamp":1717957681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":303,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1568997215001524"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.07.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725671820.793508448","asserted-by":"object"}]},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics and novel aspects of therapies in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}